Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database

被引:39
作者
Brinker, Allen D. [1 ]
Lyndly, Jenna [1 ]
Tonning, Joseph [1 ]
Moeny, David [1 ]
Levine, Jonathan G. [1 ]
Avigan, Mark I. [1 ]
机构
[1] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
SEVERE HEPATOTOXICITY; FAILURE; SAFETY; TELITHROMYCIN; CRITERIA;
D O I
10.1007/s40264-013-0116-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Early prediction and accurate characterization of risk for serious liver injury associated with newly marketed drugs remains an important challenge for clinicians, the pharmaceutical industry, and regulators. To date, a biomarker that specifically indicates exposure to a drug as the etiologic cause of liver injury has not been identified. Objectives Using cumulative proportional reporting ratios (PRRs), we investigated 'real-time' profiles of a set of pharmaceuticals, over the first 3 years of US marketing, for the signaling of clinically serious drug-induced liver injury (DILI) in a large spontaneous-reporting database. Methods Using report counts of hepatic failure or clinically serious liver injury obtained from the FDA Adverse Events Reporting System (FAERS) database, PRRs of adverse drug event terms were calculated by division of counts of domestic reports of these events by counts of all serious adverse events for each of 13 selected drugs associated with a broad range of hepatotoxic risk (including three linked to only rare instances of clinically apparent liver injury) with reference to all other drugs in the database. Drug-specific cumulative PRRs were measured at successive intervals (calendar quarters) using cumulative tallies of FAERS reports to generate time-based profiles over the initial 3 years of US marketing. Results In the set of drugs analyzed, those with no known hepatotoxic risk demonstrated time-based cumulative PRR profiles that approximate the background rates of hepatic failure and serious liver injury reported in the entire FAERS database. In contrast, those that were removed from marketing or subjected to marketing restrictions due to their potential to cause liver injury were associated with profiles of rapidly rising cumulative PRRs that were greater than 5 within the first 10 million domestic prescriptions or the first four quarters of US marketing. The systematic tracking and identification of rising PRRs for DILI associated with newly marketed pharmaceutical and biological agents is a valuable tool for identification of safety signals within the FAERS database. Limitations Disproportionality profiling of spontaneous reports in FAERS (e.g., cumulative PRR measurements), which signals an association between a recently marketed drug and liver injury, is not a method to quantitatively measure drug-related risk. Regulatory actions in response to emerging drug safety concerns often depend on an accurate assessment of risks using multiple sources of data and the consideration of overall benefits and risks of the agent. Causality must be determined through analysis of individual cases to exclude other etiologies of liver injury. Conclusion The FAERS database can be used to advance empiric hepatotoxicity time-trending reporting levels for newly marketed agents in order to rapidly identify recently launched potential hepatotoxic agents and initiate further evaluation.
引用
收藏
页码:1169 / 1178
页数:10
相关论文
共 45 条
[1]  
Andrade Raul J, 2004, Expert Opin Drug Saf, V3, P329, DOI 10.1517/14740338.3.4.329
[2]  
[Anonymous], LIV CLIN RES INF DRU
[3]   Rates of spontaneous reporting of adverse drug reactions in France [J].
Bégaud, B ;
Martin, K ;
Haramburu, F ;
Moore, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (13) :1588-1588
[4]   FALSE-POSITIVES IN SPONTANEOUS REPORTING - SHOULD WE WORRY ABOUT THEM [J].
BEGAUD, B ;
MORIDE, Y ;
TUBERTBITTER, P ;
CHASLERIE, A ;
HARAMBURU, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :401-404
[5]  
BENICHOU C, 1990, J HEPATOL, V11, P272
[6]   Drug-induced liver injury:: Hy's rule revisited [J].
Bjornsson, Einar .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (06) :521-528
[7]   Mitochondrial abnonnalities - A link to idiosyncratic drug hepatotoxicity? [J].
Boelsterli, Urs A. ;
Lim, Priscilla L. K. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 220 (01) :92-107
[8]   Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits [J].
Brinker, A ;
Beitz, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :99-102
[9]  
Brinker A., 2006, TELITHROMYCIN ASS HE
[10]   Telithromycin-Associated Hepatotoxicity: Clinical Spectrum and Causality Assessment of 42 Cases [J].
Brinker, Allen D. ;
Wassel, Ronald T. ;
Lyndly, Jenna ;
Serrano, Jose ;
Avigan, Mark ;
Lee, William M. ;
Seeff, Leonard B. .
HEPATOLOGY, 2009, 49 (01) :250-257